Product image of Liglinra (Linagliptin) supplied by GNH India

Liglinra

Active Ingredient:
Linagliptin
Origin:
EU

Liglinra (Linagliptin)

Linagliptin, the active ingredient in Liglinra, is a DPP-4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycemic control when used with diet and exercise.

GNH India supplies Liglinra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Liglinra, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels.
  • Type 2 diabetes mellitus (add‑on therapy): enhances glycaemic control when combined with metformin or other oral agents.
  • Type 2 diabetes mellitus (lifestyle adjunct): supports diet and exercise interventions to achieve target HbA1c.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in reduced hepatic glucose output and improved post‑prandial glucose control.

Side Effects

Common side effects are generally mild and transient.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory tract infection symptoms.
  • Headache: occasional mild to moderate headache.
  • Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
  • Dizziness: transient light‑headedness.
  • Upper respiratory infection: cough or sore throat.
  • Fatigue: feeling of tiredness.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with vomiting.
  • Severe hypersensitivity: rash, angioedema, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous pemphigoid: blistering skin disorder.
  • Acute renal failure: sudden decrease in urine output.
  • Cardiovascular events: rare reports of myocardial infarction.

Precautions & Warnings

Linagliptin should be used with clinical vigilance in specific patient groups.

  • Renal impairment: assess renal function before initiating therapy.
  • Hepatic impairment: monitor liver enzymes in patients with existing liver disease.
  • Elderly patients: start at the recommended dose and monitor for hypoglycaemia when combined with insulin or sulfonylureas.
  • Pregnancy and lactation: avoid use unless the potential benefit outweighs the risk; data are limited.
  • Concomitant hypoglycaemic agents: adjust dose of insulin or sulfonylureas to reduce hypoglycaemia risk.
  • Store at ambient temperature: keep below 25 °C, retain in the original container, and protect from moisture.

Avoid Interactions

Linagliptin may interact with several drug classes; interactions are categorized by clinical significance.

Major Interactions (Avoid)

  • Strong P‑glycoprotein inhibitors (e.g., itraconazole, clarithromycin): may increase linagliptin exposure.
  • Combined use with insulin or sulfonylureas without dose adjustment: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely):\n- Metformin: monitor renal function as both are renally excreted.

  • Diuretics (e.g., thiazides): may affect glucose control.
  • ACE inhibitors or ARBs: watch for additive blood pressure effects.
  • Rifampin: may reduce linagliptin plasma concentrations.
  • Anticoagulants: monitor INR if used concurrently.

Frequently Asked Questions

Liglinra contains linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It is prescribed to improve blood glucose control when used together with diet and exercise, either as monotherapy or in combination with other antidiabetic agents.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades incretin hormones such as GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion and suppresses glucagon release, leading to lower blood glucose levels after meals and throughout the day.

The dose of Liglinra is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose without medical guidance.

Safety data for linagliptin in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Liglinra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Liglinra (linagliptin) shares the same class mechanism as other DPP‑4 inhibitors but differs in its pharmacokinetic profile; it is primarily excreted unchanged via the bile, requiring no dose adjustment in mild to moderate renal impairment, unlike some alternatives that need renal dose modifications.

Liglinra tablets should be stored at ambient temperature, below 25 °C, in their original blister pack or container. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

Liglinra is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious but rare risks include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction while on the medication.

Liglinra is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is also advised for individuals with severe hepatic impairment, and it should be avoided in pregnancy unless the benefit justifies the potential risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT